首页> 美国卫生研究院文献>Springer Open Choice >Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin nab-Paclitaxel Oxaliplatin and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis

【2h】

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin nab-Paclitaxel Oxaliplatin and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis

机译：低剂量连续5-氟尿嘧啶联合白细胞素纳布-紫杉醇奥沙利铂和贝伐单抗治疗晚期胰腺癌的回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer. As a protracted low-dose infusion, 5FU is antiangiogenic, and has synergy with bevacizumab. As shown in the treatment of breast cancer, bevacizumab and nab-paclitaxel are also synergetic.

机译：背景连续输注5-氟尿嘧啶（5FU）和亚叶酸钙加nab-紫杉醇和奥沙利铂在胰腺癌患者中具有活性。作为长期的低剂量输注剂，5FU具有抗血管生成作用，并与贝伐单抗具有协同作用。如在乳腺癌的治疗中所示，贝伐单抗和纳布-紫杉醇也是协同的。

著录项

期刊名称 Springer Open Choice
作者
William H. Isacoff; Howard A. Reber; Rudolph Bedford; William Hoos; Lola Rahib; Alexander Upfill-Brown; Timothy Donahue; O. Joe Hines;
展开▼
作者单位

展开▼
年(卷),期 -1(13),4
年度 -1
页码 461–468
总页数 8
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis [J] . Isacoff William H., Reber Howard A., Bedford Rudolph, Targeted oncology . 2018,第4期

机译：低剂量连续5-氟尿嘧啶联合Leucovorin，Nab-Parlitaxel，Oxaliplatin和患有晚期胰腺癌患者的贝伐单抗：回顾性分析
2. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [J] . Landry Jerome C., Feng Yang, Prabhu Roshan S., The oncologist . 2015,第6期

机译：局部晚期直肠癌患者术前放开卡培他滨，奥沙利铂和贝伐单抗并发手术及术后5-氟尿嘧啶，白叶素，奥沙利铂（FOLFOX）和贝伐单抗的术前放疗的二期试验：5年临床结果ECOG-ACRIN癌症研究E3204组
3. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [J] . Jerome C. Landry, Yang Feng, Roshan S. Prabhu, The oncologist . 2015,第6期

机译：局部晚期直肠癌患者术前并发卡培他滨，奥沙利铂和贝伐单抗联合手术及术后5-氟尿嘧啶，白叶素，奥沙利铂（FOLFOX）和贝伐单抗的术前放疗的二期试验：5年临床结果E3204组
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Retrospective analysis of treatment-related risk of secondary malignancies among patients diagnosed and treated for childhood cancers at Cook Children's Medical Center [D] . Le, Phuong. 2011

机译：在库克儿童医学中心诊断和治疗儿童癌症的患者中与治疗相关的继发性恶性肿瘤风险的回顾性分析
6. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel Bevacizumab Leucovorin and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer [O] . Vaibhav Sahai, M. Wasif Saif, Aparna Kalyan, 2019

机译：转移性胰腺癌患者中FABLOx（5-氟尿嘧啶加nab-紫杉醇贝伐单抗白细胞素和奥沙利铂）的I / II期开放标签多中心单臂研究
7. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plusnab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer [O] . Vaibhav Sahai, M. Wasif Saif, Aparna Kalyan, 2019

机译：患有转移性胰腺癌的患者的Fablox（Menronomic 5-氟尿嘧啶Protnab-Parlitaxel，Bevacizumab，Leucovorin和Oxaliplatin）的I / II开放标签多中心研究

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin nab-Paclitaxel Oxaliplatin and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis

摘要

著录项

相似文献

相关主题

期刊订阅